DR2313 is a PARP-1; PARP-2 inhibitor (Ki = 0.23 mM). DR2313 has neuroprotective effects in both in vivo and in vitro ischemic models, and reduces cortical infarct volume in focal ischemia in rats.
特徴および利点
This compound is featured on the Caspases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Frontiers in molecular biosciences, 8, 780865-780865 (2021-12-25)
The modification of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) is associated with the regulation of numerous cellular processes. Despite the importance of O-GlcNAc in mediating cellular function our understanding of the mechanisms that regulate O-GlcNAc levels is limited. One factor known
Agents reported to activate cellular caspases include chemotherapeutic drugs, TNF receptor agonists, and other enzymes. Inhibitors of apoptosis were the first identified endogenous caspase inhibitors.
